Navidea Biopharmaceuticals NAVB Stock
Navidea Biopharmaceuticals Price Chart
Navidea Biopharmaceuticals NAVB Financial and Trading Overview
Navidea Biopharmaceuticals stock price | 0.0006 USD |
Previous Close | 0.08 USD |
Open | 0.09 USD |
Bid | 0.08 USD x 2900 |
Ask | 0.09 USD x 1800 |
Day's Range | 0.08 - 0.09 USD |
52 Week Range | 0.07 - 0.83 USD |
Volume | 1.2M USD |
Avg. Volume | 2.28M USD |
Market Cap | 2.88M USD |
Beta (5Y Monthly) | 1.531338 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5 USD |
NAVB Valuation Measures
Enterprise Value | 5.42M USD |
Trailing P/E | N/A |
Forward P/E | -0.51250005 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 43.79591 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 82.563 |
Enterprise Value/EBITDA | -0.5 |
Trading Information
Navidea Biopharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.531338 |
52-Week Change | -89.61% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.83 USD |
52 Week Low | 0.07 USD |
50-Day Moving Average | 0.17 USD |
200-Day Moving Average | 0.25 USD |
NAVB Share Statistics
Avg. Volume (3 month) | 2.28M USD |
Avg. Daily Volume (10-Days) | 2.28M USD |
Shares Outstanding | 35.06M |
Float | 25.1M |
Short Ratio | 0.17 |
% Held by Insiders | 29.41% |
% Held by Institutions | 4.97% |
Shares Short | 881.11K |
Short % of Float | 3.31% |
Short % of Shares Outstanding | 2.51% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -16665.57% |
Gross Margin | -181.70% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -229.10% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 65.65K USD |
Revenue Per Share (ttm) | 0.002 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -119295 USD |
EBITDA | -10840789 USD |
Net Income Avi to Common (ttm) | -15704126 USD |
Diluted EPS (ttm) | -0.49 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 33.8K USD |
Total Cash Per Share (mrq) | 0.001 USD |
Total Debt (mrq) | 2.32M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.129 |
Book Value Per Share (mrq) | -0.3 |
Cash Flow Statement
Operating Cash Flow (ttm) | -8152581 USD |
Levered Free Cash Flow (ttm) | -3114554 USD |
Profile of Navidea Biopharmaceuticals
Country | United States |
State | OH |
City | Dublin |
Address | 4995 Bradenton Avenue |
ZIP | 43017-3552 |
Phone | 614 793 7500 |
Website | https://www.navidea.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 11 |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Q&A For Navidea Biopharmaceuticals Stock
What is a current NAVB stock price?
Navidea Biopharmaceuticals NAVB stock price today per share is 0.0006 USD.
How to purchase Navidea Biopharmaceuticals stock?
You can buy NAVB shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Navidea Biopharmaceuticals?
The stock symbol or ticker of Navidea Biopharmaceuticals is NAVB.
Which industry does the Navidea Biopharmaceuticals company belong to?
The Navidea Biopharmaceuticals industry is Biotechnology.
How many shares does Navidea Biopharmaceuticals have in circulation?
The max supply of Navidea Biopharmaceuticals shares is 100.09M.
What is Navidea Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
Navidea Biopharmaceuticals PE Ratio is now.
What was Navidea Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
Navidea Biopharmaceuticals EPS is -0.2 USD over the trailing 12 months.
Which sector does the Navidea Biopharmaceuticals company belong to?
The Navidea Biopharmaceuticals sector is Healthcare.
Navidea Biopharmaceuticals NAVB included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NYSE AMEX COMPOSITE INDEX XAX | 5027.15 USD — |
+0.95
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}